Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Sarepta Therapeutics heads into its November 4 earnings report with nearly a quarter of its free float sold short, a stock down 19% over the past month, and a Street that has spent the past two weeks trimming price targets rather than defending the name.
The short position here is genuinely material. At 23.5% of free float, with around 24.6 million shares short, SRPT sits among the more heavily shorted names in the biotech space. The position has been broadly stable over the past 30 days, down about 3.6%, suggesting shorts are not pressing harder but are not covering either. Borrow availability remains very loose at 426%, meaning there is no squeeze pressure in the lending market: for every share currently borrowed, roughly four more remain available. Cost to borrow is negligible at 0.44%, barely changed on the week. The ORTEX short score of 65.7 places the stock in bearish territory without being at an extreme, consistent with a conviction short that has found an equilibrium rather than a trade building toward a blow-off. Options positioning is marginally more defensive than usual, with the put/call ratio at 0.59, about one standard deviation above its 20-day average of 0.55, but this is far from alarm-bell territory.
The analyst picture reinforces the cautious mood. Both RBC Capital and JP Morgan lowered price targets in the past two weeks, RBC cutting from $19 to $17 while keeping a Sector Perform rating, and JPMorgan trimming from $23 to $20 at Neutral. Those moves come on top of a Needham Underperform reiteration and a persistent Sell from HC Wainwright with a $5 target. Wolfe Research upgraded to Outperform back in July with a $27 target, and Oppenheimer maintains an Outperform at $37, but those bullish outliers are running against the recent directional current. The mean price target across the panel is $21.64, roughly 31% above the current price of $16.51. That gap looks more like a target base that has not fully repriced than a genuine bullish thesis, given the velocity of recent cuts. Valuation multiples offer little help to the bull case: the P/E has compressed to 5.9 and price-to-book to 1.07, both down sharply over 30 days, while the EPS surprise factor score ranks in just the 8th percentile, suggesting the stock has a weak track record of beating estimates.
The fundamental debate is pointed. Bulls point to Elevidys data showing slower PROMIS mobility declines in EMBARK Part 2 crossover patients versus an externally matched cohort, and the settlement of the REGENX patent dispute for $39 million removes one legal overhang. Bears counter that Q2 2026 Elevidys revenue of $98.1 million was down 3.8% sequentially, that postmarketing data on 715 treated patients showed a 19% treatment-related ALI rate including 7% serious cases, and that the randomized trial misses on NSAA have not been resolved. The Medicaid data adds texture: reimbursed dollars fell 20% year-on-year in Q1 2026, and prescription volumes dropped 30% over the same period, both as reported by the Centers for Medicare and Medicaid Services. These are not leading indicators of the earnings print, but they describe the trajectory of one payer channel heading into the report.
Institutional ownership shifts are worth noting. BlackRock raised its stake to 18.0% of shares as of September 30, and State Street reported a position of 8.4% over the same period. Those are large passive and semi-passive holders adding exposure, which partly explains why the stock has not collapsed further despite the short position and negative analyst momentum. The Vanguard Group, however, filed a 13G/A showing its stake dropped from 10.89% to effectively zero, while a related Vanguard entity, Vanguard Capital Management, has separately filed a fresh 13G showing a 5.11% stake. The restructuring of Vanguard exposure across affiliated entities makes the net change difficult to read cleanly, but the directional signal from Capital International Investors, which cut from 9.3% to 0.5%, is unambiguous. All stakes are as last disclosed around the 5% threshold; holders dropping below that level may exit without further filing.
The August 5 earnings report produced a 2.4% next-day gain and a 12.1% five-day move, the only recent data point in the history, and it came in a different price environment. With the November 4 report now 21 days away, the question is whether the sequential revenue decline in Elevidys and the Medicaid volume erosion are fully in the stock at $16.51, or whether the Street's target cuts have further to run.
See the live data behind this article on ORTEX.
Open SRPT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
